C91.31 Prolymphocytic leukemia of B-cell type, in remission

Name of the Condition

• Prolymphocytic leukemia of B-cell type, in remission
• ICD-10 Code: C91.31

Summary

Prolymphocytic leukemia of B-cell type (B-PLL) is a rare, aggressive form of chronic lymphoid leukemia characterized by the uncontrolled proliferation of mature B lymphocytes. When in remission, the disease is under control, with no evidence of active disease or symptoms. Remission typically follows successful treatment, though the condition may still require ongoing monitoring due to its aggressive nature and potential for relapse.

Causes

The exact cause of B-PLL is not fully understood, but it involves genetic mutations in B lymphocytes that disrupt normal cell regulation. Contributing factors may include environmental exposures, genetic predispositions, and alterations in immune system function. The condition is distinguished by the accumulation of prolymphocytes—larger, more immature-appearing cells than those seen in chronic lymphocytic leukemia (CLL)—which drive its aggressive behavior.

Risk Factors

• Increasing age (most common in adults over 60)
• Prior history of CLL or other lymphoid malignancies
• Certain genetic abnormalities (e.g., translocations involving chromosome 14)
• Exposure to chemotherapy or radiation (less clearly established)

Symptoms

• Rapid onset of fatigue and weakness
• Fever or night sweats
• Unexplained weight loss
• Frequent infections
• Easy bruising or bleeding
• Swollen lymph nodes, liver, or spleen
• Bone or joint pain

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess cell counts and identify abnormal lymphocytes. A bone marrow biopsy is typically performed to confirm the presence of prolymphocytes. Flow cytometry and genetic testing may be used to distinguish B-PLL from other B-cell leukemias. In remission, diagnostic tests show no evidence of active disease, though periodic monitoring is necessary.

Treatment Options

Treatment for B-PLL in remission may include targeted therapies, chemotherapy, or immunotherapy, depending on the patient’s overall health and prior response to treatment. Stem cell transplantation may be considered for eligible patients. Ongoing surveillance is essential to detect any signs of relapse.

Prognosis and Follow-Up

Prognosis for B-PLL in remission depends on factors such as age, overall health, and response to treatment. Regular follow-up appointments, including blood tests and imaging, are necessary to monitor for relapse. Early detection of recurrence can improve outcomes.

Complications

Complications may include relapse, organ infiltration, infections due to weakened immunity, and treatment-related side effects. Long-term monitoring is critical to manage these risks.

Lifestyle & Prevention

Maintaining a healthy lifestyle, including a balanced diet, regular exercise, and avoiding known carcinogens, may support overall health. However, no specific prevention strategies exist for B-PLL.

When to Seek Professional Help

Seek medical attention if symptoms such as persistent fatigue, unexplained weight loss, or signs of infection occur, as these may indicate relapse.

Tips for Medical Coders

Document the patient’s remission status clearly in the medical record, as this is essential for accurate coding. Ensure the code C91.31 is used only when remission is confirmed and documented. Verify that the diagnosis aligns with clinical findings and treatment history to avoid miscoding.